机器人与腹腔镜胃癌根治术在新辅助治疗后局部进展期胃癌中的短期与长期结局比较:一项大容量中心倾向性评分匹配回顾性研究
该单中心回顾性研究纳入2017年5月至2022年9月接受新辅助治疗后行机器人胃癌根治术(RG,n=109)或腹腔镜胃癌根治术(LG,n=212)的321例进展期胃癌患者,经1:1倾向性评分匹配后每组各106例。结果显示RG组总体并发症(13.2% vs. 28.3%,P=0.007)和手术并发症(8.5% vs. 17.9%,P=0.043)更少,淋巴结清扫总数(35.25±4.99 vs. 31.45±6.31,P<0.001)及胰上淋巴结数(13.12±4.38 vs. 10.05±4.13,P<0.001)更多,手术时间更短、出血更少,肠道功能恢复更快、住院时间更短,3年无复发生存率更优(75.5% vs. 62.3%,P=0.017),但3年总生存率无统计学差异。
要点
- RG组总体并发症和手术并发症均显著低于LG组。
- RG组淋巴结清扫总数及胰上淋巴结数显著多于LG组。
- RG组3年RFS显著优于LG组,但3年OS无统计学差异。
核心结论
- 与新辅助治疗后腹腔镜胃癌根治术相比,机器人手术显著增加淋巴结清扫数目、减少术中出血并降低术后手术并发症率。
- 机器人手术虽未在统计学上改善3年总生存率,但3年无复发生存率显著提高,可作为新辅助治疗后胃癌患者的一种替代手术方式。
研究设计与样本
- 单中心大容量中心回顾性研究,纳入2017年5月至2022年9月接受新辅助治疗后行胃癌根治术的321例进展期胃癌患者。
- 机器人胃癌根治术组109例,腹腔镜胃癌根治术组212例,经1:1倾向性评分匹配后每组各106例,比较短期临床结局与长期生存相关指标。
主要发现
- RG组总体并发症发生率为13.2%,LG组为28.3%(P=0.007);RG组手术并发症发生率为8.5%,LG组为17.9%(P=0.043)。
- RG组淋巴结清扫总数为35.25±4.99枚,LG组为31.45±6.31枚(P<0.001);RG组胰上淋巴结数为13.12±4.38枚,LG组为10.05±4.13枚(P<0.001)。
- RG组手术时间为217.62±47.49分钟,LG组为267.25±70.68分钟(P<0.001);RG组出血量为46.51±27.02毫升,LG组为70.75±37.25毫升(P<0.001)。
- RG组术后肠道功能恢复更快、流质饮食更早、住院时间更短。
- RG组3年无复发生存率为75.5%,LG组为62.3%(P=0.017);3年总生存率无统计学差异。
临床怎么用
- 对于接受新辅助治疗的进展期胃癌患者,机器人胃癌根治术在淋巴结清扫、术中出血和术后并发症方面可能优于腹腔镜手术。
- 机器人手术可能带来更快的术后恢复和更优的无复发生存,但需结合中心经验与资源可及性个体化选择。
局限性
- 本研究为单中心回顾性研究,即使采用倾向性评分匹配仍可能存在未测量混杂。
- 研究来自大容量中心,结果外推至其他中心需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although neoadjuvant therapy (NAT) for advanced gastric cancer (AGC) can benefit patient survival, few studies have compared the short- and long-term outcomes of robotic and laparoscopic gastrectomy for AGC after NAT. METHODS: The clinical data of 321 AGC patients who received NATs and who underwent robotic gastrectomy (RG, n = 109) or laparoscopic gastrectomy (LG, n = 212) between May 2017 and September 2022 were collected and analyzed retrospectively at our center. After propensity score matching (PSM) for 1:1 matching to eliminate bias, both groups had 106 cases. Short-term clinical outcomes and long-term survival-related indicators were compared between the two groups of patients. RESULTS: A total of 212 patients were included in the groups after matching. There were fewer overall complications (13.2% vs. 28.3%, P = 0.007) and surgical complications (8.5% vs. 17.9%, P = 0.043) in the RG group than in the LG group. Compared with the LG group, the RG group had more harvested overall lymph nodes (35.25 ± 4.99 vs. 31.45 ± 6.31, P < 0.001) and more suprapancreatic lymph nodes (13.12 ± 4.38 vs. 10.05 ± 4.13, P < 0.001). Patients in the RG group had significantly shorter surgery times (217.62 ± 47.49 vs. 267.25 ± 70.68, P < 0.001) and less blood loss (46.51 ± 27.02 vs. 70.75 ± 37.25, P < 0.001) than patients in the LG group. The RG group had significantly faster bowel function recovery, earlier liquid diet, and shorter hospital stay. Compared with LG, RG had a better 3-year RFS (75.5% vs. 62.3%, P = 0.017). CONCLUSION: Compared with laparoscopic surgery, robotic surgery significantly increased the number of lymph node dissected, reduced intraoperative blood loss, and postoperative surgical complications rate. Although RG did not statistically improve 3-year overall survival, there was a significant improvement in RFS and could be an alternative surgical method for GC patients after NAC.
引用
- Liu Q, Meng C, Cao S, et al. Comparison of short- and long-term outcomes of robotic versus laparoscopic gastrectomy for locally advanced gastric cancer after neoadjuvant therapy: a high-volume center retrospective study with propensity score matching. Surg Endosc. 2025. PMID: 40064692. doi:10.1007/s00464-025-11626-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。